Posted by Michael Wonder on 28 May 2024
Vasomune Therapeutics receives US FDA fast track designation for novel investigational medicine AV-001
28 May 2024 - Vasomune Therapeutics has announced today that the US FDA granted fast track designation for AV-001 for the prevention or treatment of moderate to severe ARDS in patients hospitalised with viral and/or bacterial respiratory infections.
AV-001 is a first in class fully synthetic PEGylated peptide targeting the Tie2 receptor which plays a critical role in vascular stability, barrier integrity and endothelial quiescence, particularly within the pulmonary space.
